<b>Real word effectiveness of benralizumab in mexican patients with severe eosinophilic asthma: Responders and super-responders</b>

This is the first study in Mexico to evaluate the subgroup of super-responders to benralizumab who had clinical, laboratory and quality of life improvements. Besides the vast majority were responders and 64% super-responders at 12-months of treatment.